Viracta Therapeutics, Inc.
NASDAQ:VIRX
Overview | Financials
Company Name | Viracta Therapeutics, Inc. |
Symbol | VIRX |
Currency | USD |
Price | 0.17 |
Market Cap | 6,752,540 |
Dividend Yield | 0% |
52-week-range | 0.13 - 1.31 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark Andrew Rothera |
Website | https://www.viracta.com |
An error occurred while fetching data.
About Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD